Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore
10.1038/s41397-020-00204-6
Saved in:
Main Authors: | Kim, Ji Heon, Tan, Doreen Su-Yin, Chan, Mark Yan Yee |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Language: | English |
Published: |
SPRINGERNATURE
2021
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/205785 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: A Singapore healthcare perspective
by: Chin, C.T., et al.
Published: (2014) -
Switching from Ticagrelor to Clopidogrel in Asian Patients with ST-Elevated Myocardial Infarction – A Time Dependent Analysis Study
by: Koh L, et al.
Published: (2020) -
Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome
by: Zhao, YJ, et al.
Published: (2021) -
Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine
by: Almsherqi, Z.A., et al.
Published: (2011) -
Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine
by: Almsherqi, Z.A., et al.
Published: (2016)